Literature DB >> 9794707

Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.

D R Richardson, P Ponka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9794707     DOI： 10.1016/s0022-2143(98)90049-x

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN： 0022-2143


× No keyword cloud information.
  5 in total

1.  Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool.

Authors:  Asikiya Walcourt; Joseph Kurantsin-Mills; John Kwagyan; Babafemi B Adenuga; Danuta S Kalinowski; David B Lovejoy; Darius J R Lane; Des R Richardson
Journal:  J Inorg Biochem       Date:  2013-08-26       Impact factor: 4.155

2.  A multifunctional, light-activated prochelator inhibits UVA-induced oxidative stress.

Authors:  Andrew T Franks; Qin Wang; Katherine J Franz
Journal:  Bioorg Med Chem Lett       Date:  2015-06-18       Impact factor: 2.823

3.  Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.

Authors:  Samantha Ellis; Danuta S Kalinowski; Lisa Leotta; Michael L H Huang; Peter Jelfs; Vitali Sintchenko; Des R Richardson; James A Triccas
Journal:  Mol Pharmacol       Date:  2013-11-15       Impact factor: 4.436

4.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

5.  3-Chloro-N'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy.

Authors:  Federica Sarno; Chiara Papulino; Gianluigi Franci; Jeanette H Andersen; Bastien Cautain; Colombina Melardo; Lucia Altucci; Angela Nebbioso
Journal:  Front Pharmacol       Date:  2018-09-07       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.